-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Original title:
Catia Cillóniz
Published: 2019/11/12
WeChat Link:
12 November 2019 is the 10th World Pneumonia Day. An important objective of World Pneumonia Day is to raise public awareness of pneumonia, to draw public attention to the important global clinical public health problem of pneumonia, and to develop interventions to combat, prevent and treat pneumonia., according to the 2017 Global Burden of Disease, Injury and Risk Factors Study, although pneumonia-related deaths among children under 5 years of age have fallen by 36% over the past decade, pneumonia remains the leading cause of death among such populations. Over the same period, the number of people over the age of 70 who died of pneumonia increased by 34 per cent. Streptococcus pneumoniae (Pneumococcal) remains the most common cause of disease and a major killer in children and adults.
in the current global refugee crisis, millions of displaced people do not know where to go. This group is the most vulnerable to infection, and pneumonia is one of them. Malnutrition, indoor air pollution, overcrowding, lack of medical care and limited water use all put them at risk of infection. Pneumonia is well known to have a devastating impact on vulnerable groups such as refugees, the homeless and drug addicts. But by contrast, we don't quite know the effects of pneumonia on the general population: the illusion is that
in some people, pneumonia shows only some clinical symptoms, while in others it can manifest itself as an explosive infection that causes respiratory or systemic complications and eventually leads to death. What is more, there is a general lack of a correct public understanding of the severity, complications and sequelae of pneumonia.
for community-acquired pneumonia (CAP), patients are often at higher risk for early and late heart problems such as acute myocardial infarction and arrhythmic disorders. In addition, one-third of CAP patients have sepsis, which can be life-threatening at any time. For patients with acute seizures, the probability of death increases significantly over a long period of time after recovery, possibly more than a decade, even if there have been no complications before. Public ignorance of the severity and consequences of pneumonia is also reflected in the low vaccination rates for influenza and pneumonia.。 Another important global problem is antimicrobial resistance. Rapid and widespread drug resistance in pneumonia pathogens has forced the scientific community to rethink the problem of antibiotic abuse and its consequences. Of the CAP cases diagnosed with pathogens, 1.3% were caused by drug-resistant Streptococcus pneumoniae, 1.2% by multiple drug resistance (MDR) E. coli, and 6% by multiple drug-resistant pathogens, the most common of which were Staphylococcus aureus and copper-green protons. One of the biggest problems in the clinical treatment of pneumonia caused by these drug-resistant microorganisms is how to detect these drug-resistant microorganisms as early as possible, thereby initiating appropriate antimicrobial treatment and thus preventing adverse consequences.
recent studies have shown that high mortality associated with antibiotic resistance is associated with previous complications and inadequate antimicrobial treatment.
this regard, we also very much agree with the recently published international guidelines on hospital access and ventilator-related pneumonia and CAP announcing that the concept of health-care-related pneumonia will no longer be used. We believe that by assessing regional epidemiology, the main risk factors for resistant pathogens and the severity of pneumonia, as well as by strengthening microbiological testing in patients at risk of methicillin-resistant Staphylococcus aureus (MRSA) and ductococcal bacteria, as recommended in existing CAP guidelines, it is entirely possible to improve empirical therapies and reduce mortality to avoid overuse of broad-spectrum therapies.the lung microbiome has made a major breakthrough in the pathophysiology of pneumonia, refuting the previously accepted idea that the lungs are sterile. Now we know that there are a variety of bacteria in healthy lungs that form a "lung microbiome" that continues to interact with the lungs' immune function in a balanced way.
new understanding, pneumonia has a new identity: it is the result of this balance being disrupted, and this disorder can lead to major changes in the microbiome. Further research is needed in the future to understand the role of the lung microbiome in pneumonia.over the past decade, our understanding of pneumonia has grown exponentially, but little progress has been made in patient education. The education of patients is an essential part of reducing the incidence of pneumonia, even more so in high-risk groups. We need to pass on knowledge about pneumonia to the public: publicity is imminent.
social networks are a powerful platform for patient education in the technological age in which we live. One of the main goals of the Family and Pneumonia Support and Information Association (NEUMOAI), which was founded in Spain this year, is to disseminate knowledge and provide information on pneumonia to help prevent it. Such initiatives are likely to help raise public awareness of pneumonia and encourage them to keep their lungs healthy.
(Source: Science.com)